Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Journal of Cosmetic Dermatology · 2025-07 · 24 (7)
DOI: 10.1111/jocd.70234 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 02.07.2025. Verfasst von Longyan Yao und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors, Piperidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Fund of Anhui Institute of Translational Medicine, Clinical Research Cultivation Program.
Abstract (Originalsprache)
Background
Alopecia areata (AA) is an autoimmune disorder mediated by T cells, resulting in hair loss on the scalp, eyebrows, and body. Conventional treatments for AA often exhibit high recurrence rates and various side effects. Recently, Janus kinase (JAK) inhibitors have emerged as promising therapeutic options for managing AA and several other autoimmune disorders. Case Presentation We present the case of a 26‐year‐old patient who initially responded well to Tofacitinib but subsequently experienced relapses during the treatment period. Corticosteroid therapy was effective in managing these relapses, leading to a transition to Ritlecitinib when Tofacitinib monotherapy became unsustainable.
Discussion
In cases where monotherapy proves ineffective, alternative strategies such as combination therapy, dose optimization, or switching to different therapeutic agents should be considered. While the JAK–STAT signaling pathway plays a pivotal role in the pathogenesis of AA, it is likely that additional mechanisms also contribute to its development.
Conclusion
We present a case report documenting secondary failure of tofacitinib in the treatment of AA. This case highlights potential insights into the pathogenesis of AA and may inform the development of future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
ORCID-Profile: Yongmei Lv
Förderung
- Research Fund of Anhui Institute of Translational Medicine
- Clinical Research Cultivation Program
Zitieren
APA
Yao, L., He, J., Lan, N., & Lv, Y. (2025). Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata. Journal of Cosmetic Dermatology, 24(7). https://doi.org/10.1111/jocd.70234
Vancouver
Yao L, He J, Lan N, Lv Y. Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata. Journal of Cosmetic Dermatology. 2025;24(7). doi:10.1111/jocd.70234
BibTeX
@article{Yao2025,
author = {Yao, Longyan and He, Jiumei and Lan, Na and Lv, Yongmei},
title = {Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
volume = {24},
number = {7},
doi = {10.1111/jocd.70234}
}
EUVIMED